Form 8-K - Current report:
SEC Accession No. 0001213900-24-084200
Filing Date
2024-10-02
Accepted
2024-10-01 18:46:02
Documents
15
Period of Report
2024-09-25
Items
Item 5.03: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 CURRENT REPORT ea021621601-8k_cero.htm   iXBRL 8-K 42934
2 CERTIFICATE OF DESIGNATION OF PREFERENCES, RIGHTS AND LIMITATIONS OF THE SERIES ea021621601ex3-1_cerothera.htm EX-3.1 299570
  Complete submission text file 0001213900-24-084200.txt   642662

Data Files

Seq Description Document Type Size
3 XBRL SCHEMA FILE cero-20240925.xsd EX-101.SCH 3798
4 XBRL DEFINITION FILE cero-20240925_def.xml EX-101.DEF 26673
5 XBRL LABEL FILE cero-20240925_lab.xml EX-101.LAB 36817
6 XBRL PRESENTATION FILE cero-20240925_pre.xml EX-101.PRE 25297
17 EXTRACTED XBRL INSTANCE DOCUMENT ea021621601-8k_cero_htm.xml XML 6059
Mailing Address 201 HASKINS WAY SUITE 230 SOUTH SAN FRANCISCO CA 94080
Business Address 201 HASKINS WAY SUITE 230 SOUTH SAN FRANCISCO CA 94080 650-407-2376
CERO THERAPEUTICS HOLDINGS, INC. (Filer) CIK: 0001870404 (see all company filings)

EIN.: 871088814 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-40877 | Film No.: 241344795
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)